We Accelerate Discovery

You are here


Program Snapshot

With advances in genomic sequencing and medicine, it is now possible to examine patients with rare genetic diseases at a level that allows physicians and scientists to find the “needle in a haystack”. Often times, one small change (mutation) in a genetic sequence can cause an individual to develop disease symptoms. To increase the capacity for this type of research, an Undiagnosed Diseases Network (UDN) has been established across the country to diagnose both rare and new diseases. Furthermore, through the support of mechanistic studies, the Network hopes to aid in management strategies for the patients. This program is advancing laboratory and clinical research, building upon the experience and expertise of the NIH Intramural Undiagnosed Diseases Program (UDP) and similar programs, by enhanced coordination and collaboration among laboratory and clinical researchers across multiple centers. The Network also benefits from having the capacity to share data and approaches widely throughout the scientific community.

Read more…

Program Highlights

The Cause of a Rare Neurological Disorder Uncovered by the UDN Researchers from the Undiagnosed Diseases Network have found the cause of a rare genetic disorder by combining the efforts of clinical and laboratory scientists. Read more about this study.

Female and Male sex symbolsA single mutation acts as a molecular switch for sex determination. By comparing DNA sequences from four families with sex development disorders, researchers from the Undiagnosed Diseases Network have found a single mutation that can act as a molecular switch to change the fate of sex determination but only one of these families was from the UDN. Read a brief description of the research.

Read More about the Undiagnosed Diseases Network


The UDN has been approved for phase II

The NIH Common Fund has approved the Undiagnosed Diseases Network for a second phase of support from FY18-FY22.   In phase II of the program, the UDN will continue accepting participants with unsolved medical cases as well as study the components required for network sustainability once Common Fund support ends. Pending the availability of funds, the program expects to publish funding opportunity announcements in summer 2017 to fund the second phase of the network.  Components of phase II are expected to include: a Coordinating Center, 8-10 Clinical Sites, and 3-6 Core Laboratories.


Learn more about applying to be a UDN participant here:UDN Apply

Who is in the Network?

The UDN is a group of clinical and research centers across the United States. The clinical sites are the Baylor College of MedicineDuke Medical CenterHarvard Affiliated Hospitals (Brigham and Women’s Hospital, Boston Children’s Hospital, Massachusetts General Hospital), the NIH Undiagnosed Diseases ProgramStanford Medical CenterUniversity of California at Los Angeles Medical Center, and Vanderbilt University Medical Center. The Coordinating Center for the UDN is at Harvard Medical School, and the two Sequencing Cores that perform genetic testing for the UDN are at the Baylor College of Medicine and HudsonAlpha Institute for Biotechnology with Illumina. The network also contains a central biorepository at Vanderbilt University Medical Center, a metabolomics core at Pacific Northwest National Laboratory and Oregon Health & Science University, and a model organisms screening center at Baylor College of Medicine.

UDN Sites

UDN Coordinators William Gahl and Anastasia Wise discuss the network


For more information about the UDN or application process, individuals can contact the UDN Coordinating Center by:

  • Telephone
    • Toll-free from USA, Canada, Mexico: 1-844-RING UDN (746-4836)
    • From all other countries: 1-617-432-2344

Email: UDN@hms.harvard.edu

Up to Top